Literature DB >> 28439777

Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.

Michael G Brandel1, Ali A Alattar1, Brian R Hirshman1, Xuezhi Dong1, Kate T Carroll1, Mir Amaan Ali1, Bob S Carter1, Clark C Chen2.   

Abstract

There is limited information on the management strategies and survival trends for oligodendroglioma patients. Here we used the Surveillance, Epidemiology and End Results (SEER, 1999-2012) database to analyze the historical trends of oligodendroglioma patient survival and correlate these trends to evolving clinical practice of radiation therapy (RT) use and surgical practice of gross total resection (GTR). We identified 2689 World Health Organization (WHO) grade II oligodendroglioma (abbreviated as O2) and 1191 WHO grade III oligodendroglioma (abbreviated as O3). Time-trend analyses were performed for overall survival, radiation treatment (RT) use, and extent of surgical resection (EOR). In multivariable Cox models that accounted for age, race, sex, tumor size, tumor location, EOR, and RT status, the hazard of dying from O3 has significantly decreased over the study period (p  <  0.01), while the hazard of dying from O2 has remained largely unchanged. A search of the published literature revealed articles reporting results largely supportive of these observations. The pattern of surgical practice and RT for O3 patients remained unchanged throughout the study period, suggesting that the survival improvement may be related to evolving patterns of medical management. Results from the SEER database indicate significant gains have been made in survival for O3 patients between 1999 and 2012. Such gains were not observed for O2 patients during this study period.

Entities:  

Keywords:  Oligodendroglioma; Practice pattern; SEER database; Survival; Trends

Mesh:

Year:  2017        PMID: 28439777     DOI: 10.1007/s11060-017-2430-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  44 in total

1.  The role of postoperative irradiation in the treatment of oligodendroglioma.

Authors:  D E Gannett; W M Wisbeck; D L Silbergeld; M S Berger
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-10-15       Impact factor: 7.038

2.  Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy.

Authors:  M J Taphoorn; A K Schiphorst; F J Snoek; J Lindeboom; J G Wolbers; A B Karim; P C Huijgens; J J Heimans
Journal:  Ann Neurol       Date:  1994-07       Impact factor: 10.422

Review 3.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

4.  Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  Oncologist       Date:  2011-10-03

5.  Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Authors:  Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

6.  Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and survival.

Authors:  Vinay K Puduvalli; Masood Hashmi; Leslie D McAllister; Victor A Levin; Kenneth R Hess; Michael Prados; Kurt A Jaeckle; W K Alfred Yung; Saundra S Buys; Janet M Bruner; Jeannette J Townsend; Richard Davis; Raymond Sawaya; Athanassios P Kyritsis
Journal:  Oncology       Date:  2003       Impact factor: 2.935

7.  Low-grade oligodendroglioma: an indolent but incurable disease? Clinical article.

Authors:  Hamdy El-Hateer; Luis Souhami; David Roberge; Rolando Del Maestro; Richard Leblanc; Eman Eldebawy; Thierry Muanza; Denis Melançon; Petr Kavan; Marie-Christine Guiot
Journal:  J Neurosurg       Date:  2009-08       Impact factor: 5.115

8.  Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Authors:  Gregory Cairncross; Meihua Wang; Edward Shaw; Robert Jenkins; David Brachman; Jan Buckner; Karen Fink; Luis Souhami; Normand Laperriere; Walter Curran; Minesh Mehta
Journal:  J Clin Oncol       Date:  2012-10-15       Impact factor: 44.544

9.  Trends in 5- and 10-year survival after diagnosis with childhood hematologic malignancies in the United States, 1990-2004.

Authors:  Dianne Pulte; Adam Gondos; Hermann Brenner
Journal:  J Natl Cancer Inst       Date:  2008-09-09       Impact factor: 13.506

10.  Oligodendrogliomas: the Mayo Clinic experience.

Authors:  E G Shaw; B W Scheithauer; J R O'Fallon; H D Tazelaar; D H Davis
Journal:  J Neurosurg       Date:  1992-03       Impact factor: 5.115

View more
  5 in total

1.  The Misclassification of Diffuse Gliomas: Rates and Outcomes.

Authors:  J Bryan Iorgulescu; Matthew Torre; Maya Harary; Timothy R Smith; Ayal A Aizer; David A Reardon; Jill S Barnholtz-Sloan; Arie Perry
Journal:  Clin Cancer Res       Date:  2019-01-11       Impact factor: 12.531

2.  Extent of resection and survival for oligodendroglioma: a U.S. population-based study.

Authors:  Connor J Kinslow; Andrew L A Garton; Ali I Rae; Logan P Marcus; Christopher M Adams; Guy M McKhann; Michael B Sisti; E Sander Connolly; Jeffrey N Bruce; Alfred I Neugut; Adam M Sonabend; Peter Canoll; Simon K Cheng; Tony J C Wang
Journal:  J Neurooncol       Date:  2019-08-12       Impact factor: 4.130

3.  A Population-Based Study of Treatment and Survival in Older Glioma Patients.

Authors:  Anne S Reiner; Stephanie M Lobaugh; Selin Gonen; Eli L Diamond; Katherine S Panageas
Journal:  JNCI Cancer Spectr       Date:  2022-01-05

4.  Neurosurgical patterns of care for diffuse low-grade gliomas in Sweden between 2005 and 2015.

Authors:  Louise Carstam; Anja Smits; Peter Milos; Alba Corell; Roger Henriksson; Jiri Bartek; Asgeir Store Jakola
Journal:  Neurooncol Pract       Date:  2018-07-17

5.  Moving from clinician-defined to patient-reported outcome measures for survivors of high-grade glioma.

Authors:  Lena Rosenlund; Eskil Degsell; Asgeir Store Jakola
Journal:  Patient Relat Outcome Meas       Date:  2019-08-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.